XML 50 R8.htm IDEA: XBRL DOCUMENT

Organization and Business Description	12 Months Ended
Organization and Business Description	Dec. 31, 2012
Organization and Business Description
Organization and Business Description	1. Organization and Business Description United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Our lead product, Remodulin® (treprostinil) Injection (Remodulin), was first approved for the treatment of pulmonary arterial hypertension (PAH) in 2002 by the United States Food and Drug Administration (FDA) and has also been approved for use in countries outside of the United States. We sell Remodulin in the United States and in various other countries around the world. In 2009, we received FDA approval for Tyvaso® (treprostinil) Inhalation Solution (Tyvaso) and Adcirca® (tadalafil) tablets (Adcirca), both of which we market in the United States for the treatment of PAH.